KLRC1 and B-cell chronic lymphocytic leukemia: HLA-E is the ligand for the key NK cell inhibitory receptor NKG2A, and we therefore assessed the activity of NKG2A + NK cells versus NKG2A- NK cells against selinexor-treated CLL cells (Fig. 3A).